We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging United Therapeutics (UTHR) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is United Therapeutics (UTHR - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
United Therapeutics is one of 1011 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. United Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for UTHR's full-year earnings has moved 4.6% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, UTHR has returned 3.9% so far this year. Meanwhile, stocks in the Medical group have lost about 3.9% on average. This means that United Therapeutics is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is AnaptysBio, Inc. (ANAB - Free Report) . The stock has returned 8.5% year-to-date.
In AnaptysBio, Inc.'s case, the consensus EPS estimate for the current year increased 24% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, United Therapeutics is a member of the Medical - Drugs industry, which includes 161 individual companies and currently sits at #63 in the Zacks Industry Rank. On average, stocks in this group have lost 9.2% this year, meaning that UTHR is performing better in terms of year-to-date returns.
In contrast, AnaptysBio, Inc. falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 513 stocks and is ranked #64. Since the beginning of the year, the industry has moved -12.6%.
Investors interested in the Medical sector may want to keep a close eye on United Therapeutics and AnaptysBio, Inc. as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging United Therapeutics (UTHR) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is United Therapeutics (UTHR - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
United Therapeutics is one of 1011 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. United Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for UTHR's full-year earnings has moved 4.6% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, UTHR has returned 3.9% so far this year. Meanwhile, stocks in the Medical group have lost about 3.9% on average. This means that United Therapeutics is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is AnaptysBio, Inc. (ANAB - Free Report) . The stock has returned 8.5% year-to-date.
In AnaptysBio, Inc.'s case, the consensus EPS estimate for the current year increased 24% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, United Therapeutics is a member of the Medical - Drugs industry, which includes 161 individual companies and currently sits at #63 in the Zacks Industry Rank. On average, stocks in this group have lost 9.2% this year, meaning that UTHR is performing better in terms of year-to-date returns.
In contrast, AnaptysBio, Inc. falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 513 stocks and is ranked #64. Since the beginning of the year, the industry has moved -12.6%.
Investors interested in the Medical sector may want to keep a close eye on United Therapeutics and AnaptysBio, Inc. as they attempt to continue their solid performance.